Neurological disorders in patients with thrombotic thrombocytopenic purpura

Aim: to analyze the first neurological manifestation in patient with thrombotic thrombocytopenic purpura (TTP). Material and methods. The appeals from physicians who suspected TTP were included in the study. The neurological symptoms in 40 patients with TTP were also analyzed. Results. Among 208 physician appeals about the suspicion of TTP and the referral of plasma samples for testing of ADAMTS13 activity, there were 2% of neurologists. The diagnosis of TTP was confirmed in 40 patients. 9 (22.5%) had no neurological symptoms, and 31 (77.5%) had neurological disorders. Patients with neurological symptoms were older than patients without neurological symptoms (median 37 years and 31 years, p = 0.006). Neurological symptoms were less frequently observed in pregnancy-associated TTP (p = 0.008). Among neurological symptoms there were speech disorders (40%), headache (30%), cognitive deficits (32.5%), depression of consciousness (22.5%), paresis (25%), sensation disorders (20.5%), seizures (10%). Magnetic resonance imaging/computed tomography (MRI/CT) revealed ischemic stroke in 47.5%, hemorrhagic stroke in 15%. In 6 patients, despite neurological symptoms, no pathology was detected with MRI/CT. In 4 patients, in the absence of neurological symptoms, MRI/CT revealed ischemic foci in the brain. 8 patients died: 2 patients died from sepsis, 6 - from ischemic stroke. In surviving patients, neurological symptoms regressed after remission. Conclusion. Neurological symptoms are detected in most patients with TTP. Brain MRI/CT should be performed in all patients with TTP

1. Furlan M., Robles R., Lämmle B., Lammle B., Lämmle B. Partial purifi cation and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 1996;87:4223–4234. DOI: 10.1182/blood.v87.10.4223.bloodjournal87104223

2. Sadler J.E. Pathophysiology of thrombotic thrombocytopenic purpura. Blood. 2017;130:1181–1188. DOI: 10.1182/blood-2017-04-636431

3. Silverstein А. Thrombotic thrombocytopenic purpura. The initial neurologic manifestations. Arch. Neurol. 1968;18:358–362.

4. Huang F., Li X.P., Xu, Y., Li X.Y., Li D.R., Hao Y., Yu Z.Q., Jin J., Wang J. Clinical characteristics and outcomes of adult patients with acquired thrombotic thrombocytopenic purpura: A single center retrospective study. Ann. Palliat. Med. 2021;10:5351–5358. DOI: 10.21037/apm-21-759

5. Nokes T., George J.N., Vesely S.K., Awab A. Pulmonary involvement in patients with thrombotic thrombocytopenic purpura. Eur. J. Haematol. 2014;92:156–163. DOI: 10.1111/ejh.12222

6. Hosler G.A., Cusumano A.M., Hutchins G.M. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. Arch. Pathol. Lab. Med. 2003;127:834–839. DOI: 10.5858/2003-127-834-TTPAHU

7. Amorosi E.L., Ultman J.E. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine (Baltimore). 1966;45:139–159.

8. Burrus T.M., Wijdicks E.F., Rabinstein A.A. Brain lesions are most often reversible in acute thrombotic thrombocytopenic purpura. Neurology. 2009;73:66–70. DOI: 10.1212/WNL.0B013E3181AAEA1B

9. Vendramin C., Thomas M., Westwood J.-P., Scully M. Bethesda assay for detecting inhibitory anti-ADAMTS13 antibodies in immune-mediated thrombotic thrombocytopenic purpura. TH Open. 2018;2:e329–e333. DOI: 10.1055/s-0038-1672187

10. Folstein M.F., Folstein S.E., McHugh P.R. «Mini-mental state» A practical method for grading the cognitive state of patients for the clinicia. J. Psychiatr. Res. 1975;12:189–98. DOI: 10.1016/0022-3956(75)90026-6

11. Cuker A., Cataland S.R., Coppo P., de la Rubia J., Friedman K.D., George J.N., Knoebl P.N., Kremer Hovinga J.A., Lämmle B., Matsumoto M., Pavenski K., Peyvandi F., Sakai K., Sarode R., Thomas M.R., Tomiyama Y., Veyradier A., Westwood J.P., Scully M. Redefi ning Outcomes in Immune TTP: an International Working Group Consensus Report. Blood. 2021;137(14):1855–61. DOI: 10.1182/blood.2020009150

12. Benhamou Y., Boelle P.Y., Baudin B., Ederhy S., Gras J., Galicier L., Azoulay E., Provôt F., Maury E., Pène F., Mira J.P., Wynckel A., Presne C., Poullin P., Halimi J.M., Delmas Y., Kanouni T., Seguin A., Mousson C., Servais A., Bordessoule D., Perez P., Hamidou M., Cohen A., Veyradier A., Coppo P. Cardiac troponin-i on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. experience of the french thrombotic microangiopathies reference center. J. Thromb. Haemost. 2015;13:293–302. DOI: 10.1111/jth.12790

13. Meloni G., Proia A., Antonini G., De Lena C., Guerrisi V., Capria S., Trisolini S.M., Ferrazza G., Sideri G., Mandelli F. Thrombotic thrombocytopenic purpura: prospective neurologic, neuroimaging and neurophysiologic evaluation. Haematologica. 2001;86:1194–1199.

14. Blombery P., Kivivali L., Pepperell D., Mcquilten Z., Engelbrecht S., Polizzotto M.N., Phillips L.E., Wood E., Cohney S. Diagnosis and management of thrombotic thrombocytopenic purpura (TTP) in Australia: Findings from the fi rst 5 years of the Australian TTP/thrombotic microangiopathy registry. Int. Med. J. 2016;46:71–79. DOI: 10.1111/imj.12935

15. Chiasakul T., Cuker A. Clinical and laboratory diagnosis of TTP: an integrated approach. Hematol. Am. Soc. Hematol. Educ. Progr. 2018;530–538. DOI: 10.1182/ASHEDUCATION-2018.1.530

16. Alwan F., Vendramin C., Vanhoorelbeke K., Langley K., McDonald V., Austin S., Clark A., Lester W., Gooding R., Biss T., Dutt T., Cooper N., Chapman O., Cranfi eld T., Douglas K., Watson H.G., van Veen J.J., Sibson K., Thomas W., Manson L., Hill Q.A., Benjamin S., Ellis D., Westwood J.P., Thomas M., Scully M. Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura. Blood. 2017;130:466–471. DOI: 10.1182/BLOOD-2016-12-758656

17. Weil E.L., Rabinstein A.A. Neurological manifestations of thrombotic microangiopathy syndromes in adult patients. J. Thromb. Thrombolysis. 2021;51:1163–1169. DOI: 10.1007/s11239-021-02431-5

18. Berti de Marinis G., Novello S., Ferrari S., Barzon I., Cortella I., Businaro M.A., Fabris F., Lombardi A.M. Correlation between ADAMTS13 activity and neurological impairment in acute thrombotic microangiopathy patients. J. Thromb. Thrombolysis. 2016;42:586–592. DOI: 10.1007/s11239-016-1395-7

19. Bendapud P.K., Hurwitz S., Fry A., Marques M.B., Waldo S.W., Li A., Sun L., Upadhyay V., Hamdan A., Brunner A.M., Gansner J.M., Viswanathan S., Kaufman R.M., Uhl L., Stowel C.P., Dzik W.H., Makar R.S. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol. 2017;4:e157–e164. DOI: 10.1016/S2352-3026(17)30026-1

20. Thiago J., Castro D.S., Rittner L., Appenzeller S., Yamaguti-Hayakawa G.G., Colella M., De P.E.V., Bizzacchi J.M.A., Reis F., Orsi F.A. Association of plasmic score with neurological symptoms in patients with thrombotic thrombocytopenic purpura (TTP). Blood. 2019;5:94–95. DOI: 10.1182/blood-2019-129144

21. Souilhol C., Serbanovic-Canic J., Fragiadaki M., Chico T.J., Ridger V., Roddie H., Evans P.C. Endothelial responses to shear stress in atherosclerosis: a novel role for developmental genes. Nat. Rev. Cardiol. 2020;17:52–63. DOI: 10.1038/s41569-019-0239-5

22. South K., Luken B.M., Crawley J.T.B., Phillips R., Thomas M., Collins R.F., Deforche L., Vanhoorelbeke K., Lane D.A. Conformational activation of ADAMTS13. Proc. Natl. Acad. Sci. USA. 2014;111:18578–18583. DOI: 10.1073/pnas.1411979112

23. Luken B.M., Turenhout E.A.M., Hulstein J.J.J., Van Mourik J.A., Fijnheer R., Voorberg J., 2005. The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpura. Thromb. Haemost. 2005;93:267– 274. DOI: 10.1160/TH04-05-0301

24. Upreti H., Kasmani J., Dane K., Braunstein E.M., Streiff M.B., Shanbhag S., Moliterno A.R., John Sperati C., Gottesman R.F., Brodsky R.A., Kickler T.S., Chaturvedi S. Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors. Blood. 2019;134:1037–1045. DOI: 10.1182/blood.2019001056

25. Zhang X.-H., Liang H.-M. Systematic review with network meta-analysis. Diagnostic values of ultrasonography, computed tomography, and magnetic resonance imaging in patients with ischemic stroke. Medicine (Baltimore). 2019;98:e16360. DOI: 10.1097/md.000000000001636

26. Mariotte E., Azoulay E., Galicier L., Rondeau E., Zouiti F., Boisseau P., Poullin P., de Maistre E., Provôt F., Delmas Y., Perez P., Benhamou Y., Stepanian A., Coppo P., Veyradier A. Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 defi ciency (thrombotic thrombocytopenic purpura): A cross-sectional analysis of the French national registry for thrombotic microangiopathy. Lancet Haematol. 2016;3:e237– e245. DOI: 10.1016/S2352-3026(16)30018-7

27. Galstyan G.M., Shmakov R.G., Klebanova E.E., Troitskaya V.V., Dvirnyk V.N., Surin V.L., Pshenichnikova O.S., Poznyakova Y.M., Polushkina E.S., Gaponova T.V., Mamleeva S.Yu., Pyregov A.V., Rogachevsky O.V., Sysoeva E.P., Tsvetaeva N.V. Thrombotic thrombocytopenic purpura in pregnant women: delivery cannot be interrupted. Where should I put a comma? Hematology and transfusiology. 2022;67(1):42–61. (In Russian). DOI: 10.35754/0234-5730-2022-67-1-42-61

28. Xu, J., Guan, J., Li, Q., Qian, J., Wang, Y., Huang, Y., Chen, B., Yang, Y., 2021. Sudden coma at the onset of severe refractory thrombotic thrombocytopenic purpura with successful treatment. Transfus. Apher. Sci. 2021;60:103225. DOI: 10.1016/j.transci.2021.103225

29. Aksay E., Kiyan S., Ersel M., Hudaverdi O. Thrombotic thrombocytopenic purpura mimicking acute ischemic stroke. Emerg. Med. J. 2006;23:2–3. DOI: 10.1136/emj.2006.036327.

30. Sukumar S., Brodsky M., Hussain S., Cataland S., Chaturvedi S. Cardiovascular disease is a leading cause of death in thrombotic thrombocytopenic purpura (TTP) survivors. Blood. 2020;136:22–23. DOI: 10.1182/blood-2020-138551

31. Page E.E., Kremer Hovinga J.A., Terrell D.R., Vesely S.K., George J.N. Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. Blood Adv. 2017;1:590–600. DOI: 10.1182/BLOODADVANCES.2017005124